Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 57

1.

Preceding endoscopic submucosal dissection for T1 colorectal carcinoma does not affect the prognosis of patients who underwent additional surgery: a large multicenter propensity score-matched analysis.

Yamashita K, Oka S, Tanaka S, Nagata S, Hiraga Y, Kuwai T, Furudoi A, Tamura T, Kunihiro M, Okanobu H, Nakadoi K, Kanao H, Higashiyama M, Kuraoka K, Shimamoto F, Chayama K.

J Gastroenterol. 2019 May 18. doi: 10.1007/s00535-019-01590-w. [Epub ahead of print]

PMID:
31104172
2.

Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapy.

Kaneko G, Shirotake S, Nishimoto K, Miyazaki Y, Ito K, Ito Y, Hagiwara M, Kanao K, Nakagawa K, Momma T, Asano T, Tanaka N, Mizuno R, Oya M, Oyama M.

Jpn J Clin Oncol. 2019 May 7. pii: hyz067. doi: 10.1093/jjco/hyz067. [Epub ahead of print]

PMID:
31063191
3.

Long-term prognosis after treatment for T1 carcinoma of laterally spreading tumors: a multicenter retrospective study.

Yamashita K, Oka S, Tanaka S, Nagata S, Kuwai T, Furudoi A, Tamura T, Kunihiro M, Okanobu H, Nakadoi K, Kanao H, Higashiyama M, Arihiro K, Kuraoka K, Shimamoto F, Chayama K.

Int J Colorectal Dis. 2019 Mar;34(3):481-490. doi: 10.1007/s00384-018-3203-7. Epub 2019 Jan 3.

PMID:
30607579
4.

Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma.

Ito K, Masunaga A, Tanaka N, Mizuno R, Shirotake S, Yasumizu Y, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Momma T, Masuda T, Nakagawa K, Oyama M, Asano T, Oya M.

Jpn J Clin Oncol. 2019 Jan 1;49(1):69-76. doi: 10.1093/jjco/hyy154.

PMID:
30407543
5.

Combined effects of neoadjuvant letrozole and zoledronic acid on γδT cells in postmenopausal women with early-stage breast cancer.

Sugie T, Suzuki E, Yamauchi A, Yamagami K, Masuda N, Gondo N, Sumi E, Ikeda T, Tada H, Uozumi R, Kanao S, Tanaka Y, Hamazaki Y, Minato N, Toi M.

Breast. 2018 Apr;38:114-119. doi: 10.1016/j.breast.2017.12.017. Epub 2018 Jan 5.

PMID:
29310035
6.

External Validation of the MSKCC and IMDC Risk Models in Patients Treated with Targeted Therapy as a First-line and Subsequent Second-line Treatment: A Japanese Multi-institutional Study.

Tanaka N, Mizuno R, Ito K, Shirotake S, Yasumizu Y, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Oya M.

Eur Urol Focus. 2016 Aug;2(3):303-309. doi: 10.1016/j.euf.2015.11.001. Epub 2015 Dec 2.

PMID:
28723377
7.

Gemella morbillorum bacteremia following total laparoscopic hysterectomy for uterine corpus cancer.

Miyoshi A, Miyatake T, Nishimura M, Tanaka A, Kanao S, Takeda M, Mimura M, Nagamatsu M, Yokoi T.

Gynecol Minim Invasive Ther. 2017 Apr-Jun;6(2):79-81. doi: 10.1016/j.gmit.2016.10.001. Epub 2016 Dec 5.

8.

Rare hydrosalpinx in a sexually inactive adolescent successfully treated with laparoscopy.

Takeda M, Miyatake T, Tanaka A, Kanao S, Miyoshi A, Mimura M, Nagamatsu M, Yokoi T.

Gynecol Minim Invasive Ther. 2017 Apr-Jun;6(2):76-78. doi: 10.1016/j.gmit.2016.08.005. Epub 2016 Sep 21.

9.

Long-term outcomes after treatment for T1 colorectal carcinoma: a multicenter retrospective cohort study of Hiroshima GI Endoscopy Research Group.

Tamaru Y, Oka S, Tanaka S, Nagata S, Hiraga Y, Kuwai T, Furudoi A, Tamura T, Kunihiro M, Okanobu H, Nakadoi K, Kanao H, Higashiyama M, Arihiro K, Kuraoka K, Shimamoto F, Chayama K.

J Gastroenterol. 2017 Nov;52(11):1169-1179. doi: 10.1007/s00535-017-1318-1. Epub 2017 Feb 13.

PMID:
28194526
10.

Case report of a rare pure uterine lipoma treated by laparoscopic hysterectomy.

Kanao S, Miyatake T, Tanaka A, Takeda M, Miyoshi A, Mimura M, Nagamatsu M, Yokoi T.

Gynecol Minim Invasive Ther. 2017 Jan-Mar;6(1):42-44. doi: 10.1016/j.gmit.2016.04.004. Epub 2016 Jun 14. No abstract available.

11.

Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model.

Tanaka N, Mizuno R, Yasumizu Y, Ito K, Shirotake S, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Oya M.

Urol Oncol. 2017 Feb;35(2):39.e19-39.e28. doi: 10.1016/j.urolonc.2016.10.001. Epub 2016 Nov 4.

PMID:
27825515
12.

Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma.

Shirotake S, Yasumizu Y, Ito K, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Tanaka N, Mizuno R, Oya M.

Clin Genitourin Cancer. 2016 Dec;14(6):e575-e583. doi: 10.1016/j.clgc.2016.03.014. Epub 2016 Mar 24.

PMID:
27102405
13.

Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings.

Tanaka N, Mizuno R, Shirotake S, Ito K, Yasumizu Y, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Oya M.

Urol Oncol. 2016 Jul;34(7):293.e17-25. doi: 10.1016/j.urolonc.2016.02.023. Epub 2016 Apr 1.

PMID:
27040380
14.

Etiology of Ascites and Pleural Effusion Associated with Ovarian Tumors: Literature Review and Case Reports of Three Ovarian Tumors Presenting with Massive Ascites, but without Peritoneal Dissemination.

Miyoshi A, Miyatake T, Hara T, Tanaka A, Komura N, Komiya S, Kanao S, Takeda M, Mimura M, Nagamatsu M, Yokoi T.

Case Rep Obstet Gynecol. 2015;2015:414019. doi: 10.1155/2015/414019. Epub 2015 Dec 17.

15.

Plasma fibrinogen level: an independent prognostic factor for disease-free survival and cancer-specific survival in patients with localised renal cell carcinoma.

Obata J, Tanaka N, Mizuno R, Kanao K, Mikami S, Matsumoto K, Kosaka T, Kikuchi E, Jinzaki M, Oya M.

BJU Int. 2016 Oct;118(4):598-603. doi: 10.1111/bju.13414. Epub 2016 Feb 19.

16.

Rare Primary Adenocarcinoma of the Broad Ligament: Report of Two Cases and a Literature Review.

Miyoshi A, Miyatake T, Hara T, Komiya S, Komura N, Tanaka A, Kanao S, Takeda M, Mimura M, Nagamatsu M, Yamasaki M, Yokoi T.

Int J Surg Pathol. 2016 Aug;24(5):436-42. doi: 10.1177/1066896915622690. Epub 2015 Dec 23. Review.

PMID:
26699941
17.

Long-term outcomes after treatment for pedunculated-type T1 colorectal carcinoma: a multicenter retrospective cohort study.

Asayama N, Oka S, Tanaka S, Nagata S, Furudoi A, Kuwai T, Onogawa S, Tamura T, Kanao H, Hiraga Y, Okanobu H, Kuwabara T, Kunihiro M, Mukai S, Goto E, Shimamoto F, Chayama K.

J Gastroenterol. 2016 Jul;51(7):702-10. doi: 10.1007/s00535-015-1144-2. Epub 2015 Nov 16.

PMID:
26573300
18.

Impact of Combined Use of Blood-based Inflammatory Markers on Patients with Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy: Proposal of a Cumulative Marker Score as a Novel Predictive Tool for Prognosis.

Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Miyazaki Y, Kobayashi H, Kaneko G, Hagiwara M, Ide H, Obata J, Hoshino K, Hayakawa N, Kosaka T, Hara S, Nakagawa K, Jinzaki M, Oya M.

Eur Urol Focus. 2015 Aug;1(1):54-63. doi: 10.1016/j.euf.2015.02.001. Epub 2015 May 23.

19.

Impact of an adjuvant chemotherapeutic regimen on the clinical outcome in high risk patients with upper tract urothelial carcinoma: a Japanese multi-institution experience.

Shirotake S, Kikuchi E, Tanaka N, Matsumoto K, Miyazaki Y, Kobayashi H, Ide H, Obata J, Hoshino K, Kaneko G, Hagiwara M, Kosaka T, Kanao K, Kodaira K, Hara S, Oyama M, Momma T, Miyajima A, Nakagawa K, Hasegawa S, Nakajima Y, Oya M.

J Urol. 2015 Apr;193(4):1122-8. doi: 10.1016/j.juro.2014.10.022. Epub 2014 Oct 13.

PMID:
25444957
20.

Journal Club: Diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast cancer.

Miyake KK, Nakamoto Y, Kanao S, Tanaka S, Sugie T, Mikami Y, Toi M, Togashi K.

AJR Am J Roentgenol. 2014 Aug;203(2):272-9. doi: 10.2214/AJR.13.11971.

PMID:
25055259

Supplemental Content

Loading ...
Support Center